"First half taking a breather"... Despite Daewoong Pharmaceutical's target price cut, brokerage expectations are alive, why?
DS Investment & Securities lowered Daewoong Pharmaceutical's target price from 210,000 won to 190,000 won due to Q1 earnings missing market expectations, but noted that brokerage expectations remain due to the profitability of its botulinum toxin 'Nabota'.
Key takeaway
""First half taking a breather"... Despite Daewoong Pharmaceutical's target price cut, brokerage expectations are alive, why?" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 15 out of 100. DS Investment & Securities lowered Daewoong Pharmaceutical's target price from 210,000 won to 190,000 won due to Q1 earnings missing market expectations, but noted that brokerage expectations remain due to the profitability of its botulinum toxin 'Nabota'. Reported by Maeil Business Stock on May 21, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Get the next high-impact catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.1%.